Table 1. Clinical features of 53 patients with GBCa.
| Clinical features | N (%) |
|---|---|
| Gender | |
| Male | 21 (39.6) |
| Female | 32 (60.4) |
| Age (years) | |
| ≥60 | 33 (62.3) |
| <60 | 20 (37.7) |
| PS | |
| 0 | 44 (83.0) |
| 1 | 6 (11.3) |
| ≥2 | 3 (5.7) |
| CA199 (U/mL) | |
| ≥65.0 | 34 (64.2) |
| <65.0 | 19 (35.6) |
| Lymph node metastasis | |
| Positive | 38 (71.7) |
| Negative | 15 (28.3) |
| Distant metastasis | |
| Yes | 5 (9.4) |
| No | 48 (90.6) |
| Treatment options | |
| CG | 10 (18.9) |
| CAG | 22 (41.5) |
| CCG | 21 (39.6) |
| Surgical situation | |
| Postoperative recurrence | 19 (35.8) |
| Palliative surgery | 21 (39.6) |
| No surgery | 13 (24.5) |
In this group of cases, 19 cases had postoperative recurrence; 21 cases underwent palliative surgery, including palliative cholecystectomy, laparoscopic biopsy, bile duct jejunostomy, and other surgical methods; and 13 cases did not undergo surgery. All 53 patients had a clear pathological diagnosis. Pathological specimens were mainly obtained from needle biopsy of liver metastases, palliative surgical biopsy, and laparoscopic biopsy. GBCa, advanced gall bladder cancer; PS, physical fitness score; CG, camrelizumab group; CAG, camrelizumab plus apatinib group; CCG, camrelizumab plus chemotherapy group.